The man whom clozapine (Clozaril) could not touch

doi:10.1017/9781108623872.006

Case 6: - The man whom clozapine (Clozaril) could not touch

Published online by Cambridge University Press: 03 April 2024

Rebecca Shields

Edited by

Nevena V. Radonjić ,

Thomas L. Schwartz and

Stephen M. Stahl

Show author details

Nevena V. Radonjić: Affiliation:
State University of New York Upstate Medical University
Thomas L. Schwartz: Affiliation:
State University of New York Upstate Medical University
Stephen M. Stahl: Affiliation:
University of California, San Diego

Book contents

Get access

Summary

Which of the following is true regarding clozapine (Clozaril) dosing?

Keywords

augmentation combination adjunctive treatment resistance schizoaffective disorder schizophrenia bipolar disorder tobacco use disorder plasma levels adverse effects clozapine (Clozaril)fluvoxamine (Luvox)lithium (Eskalith)aripiprazole (Abilify)olanzapine (Zyprexa)fluphenazine (Prolixin)ziprasidone (Geodon)risperidone (Risperdal)

Type: Chapter
Information: Case Studies: Stahl's Essential Psychopharmacology , pp. 87 - 108

DOI: https://doi.org/10.1017/9781108623872.006 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Ashton, AK. Aripiprazole augmentation of clozapine: in refractory schizophrenia. Psychiatry (Edgmont) 2005; 2:18–19Google Scholar PubMed

Butler, MG. Pharmacogenetics and psychiatric care: a review and commentary. J Ment Health Clin Psychol 2018; 2:17–24CrossRef Google Scholar

Dhillon, N, Heun, R. Nocturnal enuresis is an under-recognised side effect of clozapine: results of a systematic review. Global Psychiatry 2019; 2:21–30Google Scholar

Ellison, JC, Dufresne, RL. A review of the clinical utility of serum clozapine and norclozapine levels. Ment Health Clin 2015; 5:68–73CrossRef Google Scholar

Gee, S, Howes, O. Optimising treatment of schizophrenia: the role of adjunctive fluvoxamine. Psychopharmacology 2016; 233:739–40CrossRef Google Scholar PubMed

Gray, J, Risch, S. When clozapine is not enough: augment with lamotrigine? Curr Psychiatry 2009; 8:40–6Google Scholar

Hinze-Selch, D, Deuschle, M, Weber, B, et al. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 2000; 149:163–9CrossRef Google Scholar PubMed

Kane, JM, Agid, O, Baldwin, ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 2019; 80(2):18com12123CrossRef Google Scholar PubMed

Lammers, CH, Deuschle, M, Weigmann, H, et al. Coadministration of clozapine and fluvoxamine in psychotic patients – clinical experience. Pharmacopsychiatry 1999; 32:76–7CrossRef Google Scholar PubMed

Lu, ML, Lane, HY, Chen, KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000; 61:594–9CrossRef Google Scholar PubMed

Lu, ML, Lane, HY, Lin, SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004; 65:766–71CrossRef Google Scholar PubMed

Meyer, JM, Proctor, G, Cummings, MA, et al. Ciprofloxacin and clozapine: a potentially fatal but underappreciated interaction. Case Rep Psychiatry 2016; 2016:5606098Google Scholar PubMed

Meyer, JM, Stahl, SM. The Clozapine Handbook, Cambridge: Cambridge University Press, 2019CrossRef Google Scholar

Olsson, E, Edman, G, Bertilsson, L, et al. Genetic and clinical factors affecting plasma clozapine concentration. Prim Care Companion CNS Disord 2015; 17(1):10.4088/PCC.14m01704Google Scholar PubMed

Polcwiartek, C, Nielsen, J. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology 2016; 233:741–50CrossRef Google Scholar PubMed

Schwartz, D. Interpretation of clozapine levels. Graylands Hospital Drug Bulletin 2017; 24:1–8Google Scholar

Stahl, SM. Stahl’s Essential Psychopharmacology: Prescriber’s Guide, 5. Cambridge: Cambridge University Press, 2017Google Scholar

Stahl, SM. Transporters, Receptors, and Enzymes as Targets of Psychopharmacological Drug Action, 5. Cambridge: Cambridge University Press, 2021Google Scholar

Stahl, SM, Schwartz, T. Case Studies: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press, 2016CrossRef Google Scholar

Tanzer, T, Warren, N, McMahon, L, et al. Treatment strategies for clozapine-induced nocturnal enuresis and urinary incontinence: a systematic review. CNS Spectr 2022; 28(2):133–44CrossRef Google Scholar

Wigard, ME, van Gool, AR, Schulte, PF. Addition of fluvoxamine to clozapine: theory and practice. Tijdschr Psychiatr 2013; 55:113–21Google Scholar PubMed